(Reporter Li Jiewei correspondent Zhu danping) recently, Chinese Academy of Sciences Guangzhou Institute of biomedicine and health, and kashijian pharmaceutical Mulberry Handbags company (Casigen) on new diabetes drug-resistant DK3, signing exclusive overseas patent technology licensing agreement.����Under the contract, after the authority of Mulberry Handbags the biological Institute in Guangzhou Casigen company, is located in the Hong Kong Science Park, pass and have experience in pharmaceutical and biotechnology development Miu Miu Handbags in Europe and the international team, in a global context (except mainland China) further development of the new drugs, with a view to bring Gospel to diabetic patients as Miu Miu Handbags soon as possible. Meanwhile, the biological reservation of Guangzhou domestic development interest in the project.����This is bio-centres and overseas for the first time in Guangzhou pharmaceutical company signed a major new drug patent licensing contract, is to combine the advantages of international resources, exploration speed up industrialization of bio-pharmaceutical technical products a useful attempt of the path. According to reports, the new diabetes drugs